214 related articles for article (PubMed ID: 28849960)
1. Risk of bacterial vaginosis, Trichomonas vaginalis and Candida albicans infection among new users of combined hormonal contraception vs LNG-IUS.
Rezk M; Sayyed T; Masood A; Dawood R
Eur J Contracept Reprod Health Care; 2017 Oct; 22(5):344-348. PubMed ID: 28849960
[TBL] [Abstract][Full Text] [Related]
2. Nonbarrier contraceptives and vaginitis and vaginosis.
Roy S
Am J Obstet Gynecol; 1991 Oct; 165(4 Pt 2):1240-4. PubMed ID: 1951581
[TBL] [Abstract][Full Text] [Related]
3. Vaginal flora changes on Pap smears after insertion of levonorgestrel-releasing intrauterine device.
Donders GG; Berger J; Heuninckx H; Bellen G; Cornelis A
Contraception; 2011 Apr; 83(4):352-6. PubMed ID: 21397094
[TBL] [Abstract][Full Text] [Related]
4. Short- and long-term influence of the levonorgestrel-releasing intrauterine system (Mirena®) on vaginal microbiota and Candida.
Donders GGG; Bellen G; Ruban K; Van Bulck B
J Med Microbiol; 2018 Mar; 67(3):308-313. PubMed ID: 29458551
[TBL] [Abstract][Full Text] [Related]
5. Clinical importance of detection of bacterial vaginosis, trichomonas vaginalis, candida albicans and actinomyces in Papanicolaou smears.
Güdücü N; Gönenç G; Işçi H; Yiğiter AB; Başsüllü N; Dünder I
Clin Exp Obstet Gynecol; 2012; 39(3):333-6. PubMed ID: 23157037
[TBL] [Abstract][Full Text] [Related]
6. Considerations on: 'Risk of bacterial vaginosis, Trichomonas vaginalis and Candida albicans infection among new users of combined hormonal contraception vs LNG-IUS'.
Abbas AM; Shaltout AS
Eur J Contracept Reprod Health Care; 2017 Dec; 22(6):481. PubMed ID: 29043893
[No Abstract] [Full Text] [Related]
7. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
Wildemeersch D; Janssens D; Andrade A
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
[TBL] [Abstract][Full Text] [Related]
8. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
[TBL] [Abstract][Full Text] [Related]
9. One year quality of life measured with SEC-QoL in levonorgestrel 52 mg IUS users.
Cristobal I; Lete LI; Viuda E; Perulero N; Arbat A; Canals I
Contraception; 2016 Apr; 93(4):367-371. PubMed ID: 26764120
[TBL] [Abstract][Full Text] [Related]
10. Liquid-based cervical cytology and microbiological analyses in women using cooper intrauterine device and levonorgestrel-releasing intrauterine system.
Eleuterio J; Giraldo PC; Silveira Gonçalves AK; Nunes Eleuterio RM
Eur J Obstet Gynecol Reprod Biol; 2020 Dec; 255():20-24. PubMed ID: 33065517
[TBL] [Abstract][Full Text] [Related]
11. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.
Papaikonomou K; Kopp Kallner H; Söderdahl F; Gemzell-Danielsson K
Hum Reprod; 2018 Nov; 33(11):2002-2009. PubMed ID: 30295731
[TBL] [Abstract][Full Text] [Related]
12. Reactional changes in short-term levonorgestrel-releasing intrauterine system (lng-ius) use.
Giraldo PC; Souza TC; Henrique GL; Monteiro I; Amaral R; Machado RB; Discacciati MG; Sanches JM
Rev Assoc Med Bras (1992); 2019 Jul; 65(6):857-863. PubMed ID: 31340317
[TBL] [Abstract][Full Text] [Related]
13. Levonorgestrel-Releasing Intrauterine System for Women With Polycystic Ovary Syndrome: Metabolic and Clinical Effects.
da Silva AV; de Melo AS; Barboza RP; de Paula Martins W; Ferriani RA; Vieira CS
Reprod Sci; 2016 Jul; 23(7):877-84. PubMed ID: 26733500
[TBL] [Abstract][Full Text] [Related]
14. Endothelial function in women using levonorgestrel-releasing intrauterine system (LNG-IUS).
Selim MF; Hussein AF
Contraception; 2013 Apr; 87(4):396-403. PubMed ID: 23332246
[TBL] [Abstract][Full Text] [Related]
15. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
[TBL] [Abstract][Full Text] [Related]
16. The influence of the levonorgestrel-releasing intrauterine system position on bleeding patterns in reproductive age women.
Alves RDMS; Rabelo MM; Andrade VR; Cabral RCS; Merriman JW; Brito MB
Int J Gynaecol Obstet; 2019 Dec; 147(3):326-331. PubMed ID: 31489621
[TBL] [Abstract][Full Text] [Related]
17. Differences in continuation rates and early removal between contraceptive and therapeutic use of the levonorgestrel-releasing intrauterine system 52 mg.
Teunissen AM; Merry AHH; Devies IEC; Roumen FJME
Eur J Contracept Reprod Health Care; 2019 Dec; 24(6):449-456. PubMed ID: 31696740
[No Abstract] [Full Text] [Related]
18. [Study on etiologic agents of vaginitis].
Shu M; Yu P; Yiao M
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(1):80-2. PubMed ID: 11938750
[TBL] [Abstract][Full Text] [Related]
19. Use of contraceptive methods and contraceptive recommendations among health care providers actively involved in contraceptive counseling -- results of an international survey in 10 countries.
Gemzell-Danielsson K; Cho S; Inki P; Mansour D; Reid R; Bahamondes L
Contraception; 2012 Dec; 86(6):631-8. PubMed ID: 22770797
[TBL] [Abstract][Full Text] [Related]
20. Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.
Nelson AL
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):833-842. PubMed ID: 28617060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
